Business Wire

Sixth Street Welcomes Julian Salisbury as Partner and Co-Chief Investment Officer

28.7.2023 14:33:00 EEST | Business Wire | Press release

Share

Sixth Street, a leading global investment firm, today announced that Julian Salisbury will become a partner of the firm and serve as Co-Chief Investment Officer alongside Chief Executive Officer Alan Waxman and Co-President Joshua Easterly. Salisbury is expected to start in early 2024 and will help lead Sixth Street alongside Waxman, Easterly, Vice Chairman R. Martin Chavez, Co-President David Stiepleman and the firm’s Executive Committee.

Salisbury brings to Sixth Street over 25 years of experience building and leading private and public markets investing businesses. He comes to the firm after a distinguished career at Goldman Sachs, where he most recently served as Chief Investment Officer of the Asset and Wealth Management Division. In that role, he was responsible for $2.7 trillion in assets, including more than $450 billion in alternative investments. Salisbury was previously Co-Head of Goldman Sachs Asset Management and Global Head of the Merchant Banking Division.

Prior to forming Sixth Street in 2009, many of the firm’s co-founding partners worked closely with Salisbury at Goldman Sachs while building and leading investing businesses focused on growth investing, alternative energy, real estate, direct lending, and public markets strategies, among others.

“Sixth Street’s culture is the foundation of everything we do, and Julian is a seamless fit into our firm. He has distinguished himself time and again as a superstar investor and business builder and, more importantly, as a trustworthy and reliable partner,” said Sixth Street Chief Executive Officer Alan Waxman. “Julian understands how asset owners’ needs and objectives drive the flow of capital around the world, and he embodies our firm’s values of teamwork, integrity, entrepreneurship, and making a positive impact on our communities. We first got to know each other in 2002 while working on an investment in a Swiss cable company, and since then my partners and I have cheered Julian on as he has become one of the industry’s best investors and business leaders. We are incredibly excited to be back working with him again.”

Salisbury’s career is defined by an extraordinary range of investing, business-building, and leadership experience throughout the Americas, Europe, and Asia. In addition to his role as CIO of Asset and Wealth Management, he co-chaired investment committees at Goldman Sachs across all direct private strategies including growth, real estate, private credit, private equity, and infrastructure. He was named to the Goldman Sachs Management Committee in 2017 and previously co-chaired the firm’s Partnership Committee. Salisbury serves numerous charitable and community-focused organizations, including as a director on the boards of Sponsors for Educational Opportunity (SEO) and Save the Children.

“Alan and the team at Sixth Street have assembled the exact kind of organization I would want if I were creating an investment firm from the ground up. Sixth Street’s culture, platform architecture, and investment philosophy fully align with what I consider the model for how to build and operate a modern investment firm,” said incoming Sixth Street Partner and Co-Chief Investment Officer Julian Salisbury. “While leaving Goldman Sachs was a difficult decision, this was a unique opportunity to reunite with a group of people for whom I have deep, longstanding respect. Alan and I have been colleagues and friends for more than twenty years, and I am incredibly excited to work with him, Josh, David, and Marty again as a member of the powerful investing ecosystem the Sixth Street partner group has cultivated. There really is no other firm I would have considered joining, and I am excited for all that I know we will achieve together.”

As a global investment firm designed for cross-platform collaboration at scale, Sixth Street pursues a highly flexible investment mandate: the firm invests for growth, builds new partnerships, acquires assets, provides direct financing, and regularly creates first-of-their-kind capital solutions for companies and assets customized to meet the strategic objectives of management teams. Sixth Street’s more than 500 investment and control-side professionals operate as one unified team working on behalf of the firm’s institutional investors and their beneficiaries around the world. The firm’s investments and strategic partnerships across sectors and geographies have included Airbnb, AirTrunk, Bay FC, Biohaven, FC Barcelona, Legends, Real Madrid, San Antonio Spurs, and Spotify, among many others.

About Sixth Street

Sixth Street is a leading global investment firm with over $65 billion in assets under management and committed capital. The firm’s Sixth Street TAO platform also includes Talcott Financial Group, an international life insurance group with $123 billion in assets under management. Sixth Street uses its long-term flexible capital, data-enabled capabilities, and One Team culture to develop themes and offer solutions to companies across all stages of growth. For more information, follow Sixth Street on social media and visit www.sixthstreet.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Sixth Street
Patrick Clifford
pclifford@sixthstreet.com
+1-646-906-4339

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye